Back to top
more

Kura Oncology (KURA)

(Real Time Quote from BATS)

$20.68 USD

20.68
560,255

+0.09 (0.44%)

Updated May 3, 2024 09:48 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 27% (69 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for KURA

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

Kura Oncology, Inc. [KURA]

Reports for Purchase

Showing records 21 - 40 ( 254 total )

Company: Kura Oncology, Inc.

Industry: Medical - Biomedical and Genetics

Record: 21

11/03/2023

Company Report

Pages: 7

Q3 Financials; Zifto Still Standing Out

Provider: Wedbush Securities Inc.

Analyst: DRISCOLL R

Price: 12.50

Research Provided by a Third Party

Company: Kura Oncology, Inc.

Industry: Medical - Biomedical and Genetics

Record: 22

11/03/2023

Daily Note

Pages: 24

MORNING CALL

Provider: Wedbush Securities Inc.

Analyst: Research Department

Price: 35.00

Research Provided by a Third Party

Company: Kura Oncology, Inc.

Industry: Medical - Biomedical and Genetics

Record: 23

11/03/2023

Company Report

Pages: 9

3Q23 Results; New Collaboration Expands KO-2806’s Combo Potential; KOMET-007 and -001 Updates in 1H24

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: Kura Oncology, Inc.

Industry: Medical - Biomedical and Genetics

Record: 24

11/01/2023

Company Report

Pages: 6

Optimized Entry and Exit Levels for KURA 11123

Provider: Stock Traders Daily

Analyst: Research Department

Price: 12.50

Research Provided by a Third Party

Company: Kura Oncology, Inc.

Industry: Medical - Biomedical and Genetics

Record: 25

11/01/2023

Industry Report

Pages: 18

Biotechnology-The Wedbush Monthly Check-Up: November 2023

Provider: Wedbush Securities Inc.

Analyst: CHICO L

Price: 25.00

Research Provided by a Third Party

Company: Kura Oncology, Inc.

Industry: Medical - Biomedical and Genetics

Record: 26

10/21/2023

Company Report

Pages: 6

Optimized Entry and Exit Levels for KURA 102123

Provider: Stock Traders Daily

Analyst: Research Department

Price: 12.50

Research Provided by a Third Party

Company: Kura Oncology, Inc.

Industry: Medical - Biomedical and Genetics

Record: 27

10/19/2023

Daily Note

Pages: 6

FIT-001 Phase 1 Trial With KO-2806 Kicks Off as First Patient Dosed

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: Kura Oncology, Inc.

Industry: Medical - Biomedical and Genetics

Record: 28

10/18/2023

Daily Note

Pages: 10

MORNING CALL

Provider: Wedbush Securities Inc.

Analyst: Research Department

Price: 12.50

Research Provided by a Third Party

Company: Kura Oncology, Inc.

Industry: Medical - Biomedical and Genetics

Record: 29

10/18/2023

Company Report

Pages: 8

Tipifarnip Continues to Tip the Scales in Favor of FTIs in Advanced Solid Tumors

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: Kura Oncology, Inc.

Industry: Medical - Biomedical and Genetics

Record: 30

10/18/2023

Daily Note

Pages: 5

AIM-HN Data at ESMO; FTI’s AIMing Higher

Provider: Wedbush Securities Inc.

Analyst: DRISCOLL R

Price: 5.00

Research Provided by a Third Party

Company: Kura Oncology, Inc.

Industry: Medical - Biomedical and Genetics

Record: 31

10/11/2023

Company Report

Pages: 6

Optimized Entry and Exit Levels for KURA 101123

Provider: Stock Traders Daily

Analyst: Research Department

Price: 12.50

Research Provided by a Third Party

Company: Kura Oncology, Inc.

Industry: Medical - Biomedical and Genetics

Record: 32

10/05/2023

Industry Report

Pages: 14

Biotechnology- EORTC-NCI-AACR 2023 Abstract Roundup for Covered Companies

Provider: Wedbush Securities Inc.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: Kura Oncology, Inc.

Industry: Medical - Biomedical and Genetics

Record: 33

10/02/2023

Company Report

Pages: 11

Parallel Advancement of Revumenib and Ziftomenib Validate Menin Inhibition in Acute Leukemias

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: Kura Oncology, Inc.

Industry: Medical - Biomedical and Genetics

Record: 34

10/02/2023

Industry Report

Pages: 20

The Wedbush Monthly Check-Up: October 2023

Provider: Wedbush Securities Inc.

Analyst: CHICO L

Price: 25.00

Research Provided by a Third Party

Company: Kura Oncology, Inc.

Industry: Medical - Biomedical and Genetics

Record: 35

10/02/2023

Daily Note

Pages: 6

SNDX Shares Pivotal Revumenib Data in KMT2Ar AML; NDA Filing by YE:23

Provider: Wedbush Securities Inc.

Analyst: DRISCOLL R

Price: 12.50

Research Provided by a Third Party

Company: Kura Oncology, Inc.

Industry: Medical - Biomedical and Genetics

Record: 36

10/01/2023

Company Report

Pages: 6

Optimized Entry and Exit Levels for KURA 10123

Provider: Stock Traders Daily

Analyst: Research Department

Price: 12.50

Research Provided by a Third Party

Company: Kura Oncology, Inc.

Industry: Medical - Biomedical and Genetics

Record: 37

09/29/2023

Daily Note

Pages: 8

MORNING CALL

Provider: Wedbush Securities Inc.

Analyst: Research Department

Price: 12.50

Research Provided by a Third Party

Company: Kura Oncology, Inc.

Industry: Medical - Biomedical and Genetics

Record: 38

09/28/2023

Daily Note

Pages: 5

To Ignore This Would Be KRAS; More Compelling Preclinical Data for KO-2806

Provider: Wedbush Securities Inc.

Analyst: DRISCOLL R

Price: 5.00

Research Provided by a Third Party

Company: Kura Oncology, Inc.

Industry: Medical - Biomedical and Genetics

Record: 39

09/28/2023

Company Report

Pages: 9

Promising First Preclinical Data For KO-2806 in NSCLC Set the Stage for Phase 1 FIT-001 Launch by YE23

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: Kura Oncology, Inc.

Industry: Medical - Biomedical and Genetics

Record: 40

09/21/2023

Company Report

Pages: 6

Optimized Entry and Exit Levels for KURA 92123

Provider: Stock Traders Daily

Analyst: Research Department

Price: 12.50

Research Provided by a Third Party